Source BioScience Teams Up to Develop State-of-the-art Pathology Tests for Improved Patient Care
Source BioScience, the international laboratory products and services business, has combined forces with The University of Nottingham, Nottingham University Hospitals NHS Trust and several industrial partners to form “The Nottingham Molecular Pathology Node for Integrated Multi-platform Biomarker Research and Knowledge Transfer”, a collaboration dedicated to advancing the field of precision medicine.
Precision medicine is an approach which subdivides patients with a shared disease into groups based on, for example, the severity of their disease and how they respond to different treatments. By stratifying patients into different groups, doctors can predict the most effective and safe intervention for individual patients. Moreover, by understanding the mechanisms that underpin these differences, new interventions can be developed for patients whose needs are not currently met.
Financially backed by the Medical Research Council (MRC) and the Engineering and Physical Sciences Research Council (EPSRC), the Nottingham Molecular Pathology Node is one of only six nodes across the UK. Each of which will work to develop innovative molecular pathology tests to enable superior diagnosis and treatment of disease, using a customised approach.
In particular, the Nottingham Molecular Pathology Node will bring together informatics, computational modelling and molecular pathology to develop world-leading translational molecular diagnostic capabilities for gastrointestinal, liver and respiratory diseases.
Molecular pathology plays an essential role in precision medicine. Using only a small blood or tissue sample, biomarkers of disease progression/response to therapy can be identified and used in combination with clinical data and other information to stratify the patients.
Professor Alan Knox, Professor in Respiratory Medicine, and Head of the School of Medicine's Division of Respiratory Medicine at The University of Nottingham, said:
“This research will help ensure that in future patients are treated with the right drug for their condition at the most appropriate time and there will be suitable biomarkers to individually evaluate patients' responses to treatment. In the medium to long term this is likely to improve the quality of life and longevity of patients with a number of conditions, who currently have high morbidity and mortality. There is therefore a real possibility of a major impact on the nation's health.”
Dr Tom Burr, Scientific and Technical Director at Source BioScience said:
“We are delighted to be part of this ground-breaking research which will undoubtedly help to realise the potential of personalised medicine. By contributing our knowledge and expertise to this collaboration we can help to develop the necessary tools to bring about this change and in doing so enhance our ability to deliver state-of-the-art molecular pathology tests to the healthcare community.”